Effect of albumin fusion on the biodistribution of interleukin-2

Cancer Immunology, Immunotherapy

Volumn 53, Issue 5, 2004, Pages 404-410

  Yao, Zhengsheng ^a   Dai, Weili ^a   Perry, James ^a   Brechbiel, Martin W ^b   Sung, Cynthia ^a  

^a GLAXOSMITHKLINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

111In radiolabeling; Albuleukin; Biodistribution; Interleukin 2; Mice; Whole body autoradiography

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL)CYCLOHEXYL DIETHYLTRIAMINEPENTAACETIC AICD; ACETIC ACID DERIVATIVE; ALBULEUKIN; CHELATING AGENT; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; INDIUM 111; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; INTERLEUKIN 2; ISOTHIOCYANIC ACID DERIVATIVE; N (2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE 1,2 DIAMINE N,N',N',N'',N'' PENTAACETIC ACID; N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID; PENTETIC ACID; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY; LIVER; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN TRANSPORT; RADIOACTIVITY; SPLEEN; T LYMPHOCYTE; TISSUE DISTRIBUTION; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RADIOIMMUNOASSAY;

ANIMALS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; ISOTHIOCYANATES; KIDNEY; LIVER; LYMPH NODES; MICE; MICE, INBRED BALB C; PENTETIC ACID; RADIOIMMUNODETECTION; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; SPLEEN; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 2342628432     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0454-z     Document Type: Article

References (26)

1. Chianelli M, Signore A, Fritzberg AR, Mather SJ (1997) The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 24:579
2. Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203
3. Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA (1984) In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res 44:1380
4. Gennuso R, Spigelman MK, Vallabhajosula S, Moore F, Zappulla RA, Nieves J, Strauchen JA, Paciucci PA, Malis LI, Goldsmith SJ, Holland JF (1989) Systemic biodistribution of radioiodinated interleukin-2 in the rat. J Biol Response Mod 8:375
5. Kammula US, White DE, Rosenberg SA (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797
6. Katre NV, Knauf MJ, Laird WJ (1987) Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA 84:1487
7. Kobayashi H, Wu C, Yoo TM, Sun BF, Drumm D, Pastan I, Paik CH, Gansow OA, Carrasquillo JA, Brechbiel MW (1998) Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 39:829
8. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, Bradley EC (1990) Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 50:2009
9. 35S-labeled recombinant interleukin-2 in mice. Cell Molec Biol Lymphokines 3:779
10. Kwack K, Lynch RG (2000) A new non-radioactive method for IL-2 bioassay. Mol Cell 10:575
11. Melder RJ, Osbore B, Wang Q, Lu J, Miceli R, Bao S (2003) Albuleukin (TM), an interleukin-2/human serum albumin fusion protein, inhibits B16F10 melanoma. 94th Annual Meeting of the American Association for Cancer Research 44:1298
12. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, Schlom J, Brechbiel MW (2002) In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29:431
13. Nadeau RW, Satoh H, Scheide S, Crowl R, Conroy R, Garland WA, Liberate DJ (1995) A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I] recombinant human interleukin-2 in cynomolgus monkeys. Drug Metab Dispos 23:904
14. Ohnishi H, Chao JT, Lin KK, Lee H, Chu TM (1989) Role of the kidney in metabolic change of interleukin-2. Tumour Biol 10:202
15. Ohnishi H, Lin KM, Chu TM (1990) Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res 50:1107
16. Regoeczi E (1987) The body iodine pool. CRC Press, Boca Raton, Florida, p 48
17. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380
18. 14C-labeled recombinant human interleukin-2 in the rat. Lymphokine Cytokine Res 11:229
19. 125I-interleukin-2 in mice. Int J Immunopharmacol 11:411
20. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM (1990) Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 50:2330
21. 123I-interleukin-2: an early sign of type 1 diabetes. Lancet 2:537
22. 123I-interleukin-2. Labelling procedure and animal studies. Nucl Med Commun 13:713
23. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169
24. Sung C, Youle RJ, Dedrick RL (1990) Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res 50:7382
25. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC (1999) Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162:43
26. Yao Z, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, Waldmann TA, Eckelman WC, Paik CH, Carrasquillo JA (2001) Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 42:1538